Beam Therapeutics Founded by Gene Editing Pioneers to Create Precision Genetic Medicines with Base Editing
Base editing technology builds on CRISPR to enable single-letter editing...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
We are seeking an innovative, drug discovery leader, expert in hematological diseases. The individual will lead our drug discovery effortsRead More
We are seeking an innovative and experienced Formulation and Delivery Technologies leader. The individual will lead our efforts in establishingRead More
We are seeking an innovative, collaborative and accomplished research leader to be the Head of Cell Biology, our core cellRead More
325 Vassar Street
Cambridge, MA 02139